The immunogenicity of breast cancer-molecular subtypes matter

Annals of Oncology

Volumn 25, Issue 8, 2014, Pages 1453-1455

  Denkert, C ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIBODY; CD8 ANTIGEN; CELL MARKER; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGRAMMED DEATH 1 ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1 ANTIBODY; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ADJUVANT CHEMOTHERAPY; BREAST CANCER; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; EDITORIAL; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOGENICITY; LYMPHOCYTIC INFILTRATION; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MOLECULAR TYPING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; TUMOR MICROENVIRONMENT; BREAST TUMOR; FEMALE; IMMUNOLOGY; MORTALITY; PATHOLOGY; TUMOR ASSOCIATED LEUKOCYTE; ANTIGEN FUNCTION; CANCER RISK; DISEASE ASSOCIATION; DISEASE MARKER; LYMPHOCYTE FUNCTION; MEDICAL RESEARCH; MOLECULAR DYNAMICS; OUTCOME ASSESSMENT; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RISK ASSESSMENT; RISK FACTOR; TUMOR IMMUNITY;

BREAST NEOPLASMS; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING;

EID: 84905159046     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu235     Document Type: Editorial

References (18)

1. Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366(26): 2455-2465.
2. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454.
3. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
4. Azimi F, Scolyer RA, Rumcheva P et al. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol 2012; 30(21): 2678-2683.
5. Perou CM, Sørlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406(6797): 747-752.
6. Denkert C, Loibl S, Noske A et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010; 28: 105-113.
7. Issa-Nummer Y, Darb-Esfahani S, Loibl S et al. Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer-a substudy of the neoadjuvant GeparQuinto trial. PLoS One 2013; 8: e79775.
8. Loi S, Sirtaine N, Piette F et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicinbased chemotherapy: BIG 02-98. J Clin Oncol 2013; 31: 860-867.
9. Ali HR, Provenzano E, Dawson SJ et al. Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients. Ann Oncol 2014; 25: 1536-1543.
10. Chen Z, Chen X, Zhou E et al. Intratumoral CD8+ cytotoxic lymphocyte is a favorable prognostic marker in node-negative breast cancer. PLoS One 2014; 9(4): e95475.
11. Seo AN, Lee HJ, Kim EJ et al. Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer 2013; 109(10): 2705-2713.
12. West NR, Milne K, Truong PT et al. Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res 2011; 13(6): R126.
13. Baker K, Lachapelle J, Zlobec I et al. Prognostic significance of CD8+ Tlymphocytes in breast cancer depends upon both oestrogen receptor status and histological grade. Histopathology 2011; 58(7): 1107-1116.
14. Liu S, Lachapelle J, Leung S et al. CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. Breast Cancer Res 2012; 14(2): R48.
15. Mahmoud SM, Paish EC, Powe DG et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 2011; 29(15): 1949-1955.
16. Mahmoud SM, Paish EC, Powe DG et al. An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer. Breast Cancer Res Treat 2011; 127: 99-108.
17. Kim S, Lee A, Lim W et al. Zonal difference and prognostic significance of foxp3 regulatory T cell infiltration in breast cancer. J Breast Cancer 2014; 17(1): 8-17.
18. West NR, Kost SE, Martin SD et al. Tumour-infiltrating FOXP3(+) lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer. Br J Cancer 2013; 108(1): 155-162.